BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Revenue (Most Recent Fiscal Year) | $9.30M |
Net Income (Most Recent Fiscal Year) | $-643.20M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 473.08 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -7021.94% |
Net Margin (Trailing 12 Months) | -6913.92% |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -110.39% |
Current Ratio (Most Recent Fiscal Quarter) | 3.32 |
Quick Ratio (Most Recent Fiscal Quarter) | 3.32 |
Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $-7.72 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.96 |
Earnings per Share (Most Recent Fiscal Year) | $-3.95 |
Diluted Earnings per Share (Trailing 12 Months) | $-3.94 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 175.83M |
Free Float | 125.69M |
Market Capitalization | $4.40B |
Average Volume (Last 20 Days) | 1.52M |
Beta (Past 60 Months) | 1.03 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 28.52% |
Percentage Held By Institutions (Latest 13F Reports) | 99.85% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |